Glaxo And SuperGen Team Up In An Option Deal For Cancer Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will pay $5 million upfront for an option to develop cancer drugs based on epigenetic targets; deal is GSK's sixth option-alliance this year.